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Abstract
Introduction: Hepatocyte growth factor (HGF) is a strong mitogen stimulating lung epithelial cell growth. Elevated levels of
HGF have been reported in various biological materials of patients with acute respiratory distress syndrome and in patients
recovering from pneumonia or pneumonectomy. Sarcoidosis may be complicated by lung fibrosis. Consequently, HGF could
be considered a new biomarker identifying patients with a higher risk of lung fibrosis.
The aim of the study was to verify whether: 1. HGF is measurable in bronchoalveolar lavage fluid (BALF) and exhaled breath
condensate (EBC); 2. HGF in BALF or EBC is impaired in sarcoidosis; and 3. HGF correlates with chosen activity and
prognostic markers.
Material and methods: Sixty-four EBC and 30 BALF of sarcoid patients, and 15 and 9 of healthy controls, respectively, were
collected for the measurement of HGF using an ELISA test.
Results: HGF was detectable in 62% of EBC samples (56% sarcoidosis and 87% of controls) and in all the BALF samples.
EBC and BALF concentrations were not different in comparison to the controls. Moreover, no correlation was found between
EBC/BALF concentrations and radiological stage, lung function tests, duration of disease, number of relapses, BALF lympho-
cytes, serum ACE, or serum and urine calcium concentrations.
Conclusions: HGF is detectable in BAL and EBC. However, it does not distinguish sarcoidosis patients from healthy
subjects. The above, as well as the lack of correlations with various parameters of disease activity and severity rule out EBC/
/BALF HGF as a biomarker for sarcoidosis monitoring.
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Streszczenie
Wstęp: Wątrobowy czynnik wzrostu (HGF) jest silnym mitogenem stymulującym wzrost komórek nabłonka pęcherzyków
płucnych. Wyższe stężenia HGF w różnych materiałach biologicznych stwierdzono między innymi w zespole ostrej niewydol-
ności oddechowej (ARDS), u chorych po przebytym zapaleniu płuc i po pneumonektomii. Niekorzystnym zejściem sarkoidozy
jest włóknienie płuc. Wątrobowy czynnik wzrostu mógłby być przydatny jako marker pozwalający na rozpoznanie chorych
obarczonych ryzykiem włóknienia płuc.
Celem pracy była ocena: 1) czy HGF jest wykrywalny w popłuczynach oskrzelowo-pęcherzykowych (BAL) i kondensacie
powietrza wydechowego (EBC); 2) czy stężenia HGF w BAL-u i kondensacie chorych na sarkoidozę różnią się od stężeń osób
zdrowych; 3) czy istnieją korelacje z parametrami aktywności i wybranymi czynnikami rokowniczymi.
Materiał i metody: Zebrano kondensat od 64 i popłuczyny oskrzelowo-pęcherzykowe od 30 chorych na sarkoidozę. Grupę kontrolną
stanowiły osoby zdrowe (n = 15 dla EBC, n = 9 dla BAL). Wątrobowy czynnik wzrostu oznaczono immunoenzymatycznie.
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Wyniki: Stężenia HGF w kondensacie przekroczyły próg detekcji u 62% badanych (56% chorych i 87% zdrowych) i we
wszystkich próbkach BAL. Nie stwierdzono różnic w stężeniach w EBC i BAL pomiędzy osobami chorymi i zdrowymi. Nie
stwierdzono korelacji pomiędzy HGF w EBC/BALF a stopniem radiologicznym, parametrami czynności płuc, czasem trwania
choroby, liczbą nawrotów, odsetkiem limfocytów w BAL, stężeniem enzymu konwertującego angiotensynę i wapnia
w surowicy, utratą dobową wapnia z moczem.
Wnioski: Wątrobowy czynnik wzrostu jest wykrywalny w BAL i EBC. Jednak brak różnic pomiędzy chorymi na sarkoidozę
i osobami zdrowymi oraz brak korelacji z markerami aktywności i czynnikami rokowniczymi uniemożliwiają jego zastosowa-
nie w diagnostyce i monitorowaniu sarkoidozy.
Słowa kluczowe: sarkoidoza, kondensat powietrza wydechowego, popłuczyny oskrzelowo-pęcherzykowe, wątrobowy
czynnik wzrostu
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Introduction
Although the majority of patients suffering
from sarcoidosis have a good prognosis due to
a high rate of spontaneous resolution [1], those suf-
fering from a chronic disease have a significant risk
of developing lung fibrosis [2].
Hepatocyte growth factor (HGF) is a strong
mitogen for lung epithelial cells [3]. Bleomycin in-
stillation to a rat’s lung results in a 10-fold incre-
ase of HGF concentration in BALF [4]. HGF is pro-
tective in many animal models of lung injury [5].
Elevated levels of HGF have been found in the pul-
monary oedema fluid of patients with acute lung
injury, with higher concentrations in those with
worse prognosis [6]. Production of this molecule
by fibroblasts of patients suffering from emphyse-
ma is defective [7]. The role of HGF in lung rege-
neration may also be illustrated by increased serum
concentrations in patients recovering from surgical
lung resection [8]. In addition, elevated HGF con-
centrations in the exhaled breath condensates (EBC)
of patients suffering from pneumonia have been re-
ported [9]. HGF in BAL fluid has recently been re-
ported to be higher in active, compared to inactive,
sarcoidosis. The authors reported that HGF can pre-
vent TGF-b-induced myofibroblast transformation
in vitro. As a result, they propose a new mechanism
of antifibrotic activity of HGF [10].
Bearing in mind all of the above data, we fo-
und it interesting to measure HGF concentrations
in the EBC and bronchoalveolar lavage fluid
(BALF) of patients suffering from sarcoidosis.
 Material and methods
Exhaled breath condensates samples were col-
lected from 64 patients and BALF samples were
collected from 30 patients with active sarcoidosis.
Sarcoidosis was confirmed by biopsy of the lung,
mediastinal/hilar lymph nodes, or bronchial mu-
cosa, with the exception of patients with typical
radiological picture consistent with stage I/II with
typical BAL pattern and Löfgren syndrome. None
of the patients has been treated at the time of ma-
terial collection. All patients were diagnosed with
active sarcoidosis, based on clinical symptoms, ra-
diological progression, increased BAL lymphocy-
tes, increased SACE, or impaired calcium metabo-
lism. There were 14 ex-smokers of cumulative ci-
garette consumption below 10 pack-years and the
shortest time of abstinence was longer than 1 year.
The rest of the group consisted of never-smokers.
A control group for EBC consisted of 15 heal-
thy never-smoking volunteers. A control group for
BALF comprised 9 healthy never-smokers. Bron-
choscopy with BAL was performed in these sub-
jects due to medical indications, but bronchosco-
py, BAL, CT, and lung function tests were normal.
There were 2 patients with episodes of blood-sta-
ined sputum, finally found to be caused by epista-
xis, and 7 patients with suspected hilar/mediasti-
nal mass based on chest X-ray, in whom this pa-
thology was finally excluded on the basis of CT.
All the patients signed informed consent forms
for participation in the study. In addition, all the pa-
tients undergoing bronchoscopy also signed a sepa-
rate standard consent for the procedure. The study
was approved by the Ethical Committee at the Medi-
cal University of Lodz (consent No. RNN/99/08/KE).
Exhaled breath condensate was collected ac-
cording to the standards [11], using a commercial
device (Ecoscreen, Jaeger, Germany), always befo-
re bronchoscopy. Briefly, the patients were asked
to breathe out spontaneously through a mouthpie-
ce equipped with a saliva trap for ten minutes. The
respiratory rate ranged from 15 to 20 breaths/min.
All the subjects wore a nose-clip and rinsed their
mouths with distilled water just before and during
the seventh minute of the collection in order to re-
duce nasal contamination. The samples were sto-
red at –80 oC until analysis.
Bronchoalveolar lavage fluid was collected
during a routine bronchoscopy, by instillation and
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subsequent withdrawal of 4 × 50 ml of 0.9% NaCl
to the medial lobe or lingula. The fluid was filte-
red and cytospin slides were prepared and stained
with May-Grünwald-Giemsa stain. The total num-
ber of cells and the percentage of particular cell
types were calculated. The supernatants were sto-
red at –80 oC until analysis.
The following tests were performed: chest
X-ray (CXR), high resolution computed tomography
(HRCT), lung function tests (FEV1, FVC, FEV1/FVC,
DLCO), blood tests (serum angiotensin converting
enzyme [SACE], C-reactive protein [CRP], and se-
rum calcium concentrations) and 24-hour urine
collection for calcium loss.
Human HGF was measured with the use of an
immunoassay kit (BioSource Europe S.A., Belgium).
Each sample was measured in duplicate, and a mean
value was calculated. The detection limit was 20 pg/
/mL. The levels of the measured mediators below the
detection limit were arbitrarily assumed to be half
of the detection limit value. The intra-assay repro-
ducibility (CV, coefficient of variation) for EBC was
20.1% and for BAL was 16.3%. According to the
manufacturer, the intra-assay reproducibility for
human serum was < 6.1%, the inter-assay repro-
ducibility was < 7.0%, and recovery after addition
of Hu HGF to human serum was 94–102%.
Statistical analysis
The data were presented as mean ± SEM. The
Mann-Whitney test was used to compare sarcoido-
sis EBC HGF concentrations with the control gro-
up (non-Gaussian distribution of sarcoidosis EBC
data), and Student’s t-test was used to compare
BALF HGF concentrations. The correlations were
calculated with the Spearman test. One-way ANO-
VA and Bonferroni post-test (for data with Gaus-
sian distribution) or Kruskall-Wallis followed by
Dunn’s Multiple Comparison Test (for data with-
out normal distribution) were used to calculate dif-
ferences between data characterizing sarcoidosis
stages (see Table 1). P < 0.05 was assumed as sta-
tistically significant.
None of the authors has any conflict of interest.
Results
Hepatocyte growth factor was detectable in 62%
of EBC samples (56% of the sarcoidosis and 87% of
control samples). All the BALF HGF concentrations
were above the detection limit of 20 pg/ml.
No differences were found between the sarco-
id and control HGF EBC concentrations (40.9 ± 4.8
vs. 52.1 ± 8.1 pg/ml), or HGF BALF concentrations
(141.0 ± 8.0 v. 121.4 ± 14.4 pg/ml) (Fig. 1).
Table 1. Characteristics and results of measurements in sarcoidosis group (n = 64) depending on radiological stage
Measurement Stage 1 Stage 2 Stage 3 Statistical analysis
EBC HGF [pg/ml] 42.9 ± 8.0 30.2 ± 5.3 56.5 ± 16.6 NS
BALF HGF [pg/ml]# 140.8 ± 8.5 141.4 ± 16.4 140.2 ± 37.5 NS
Age (years) 39 ± 2 42 ± 2 40 ± 3 NS
LS (%) 29 11 0 Not calculated
No. of episodes 1.13 ± 0.07 1.05 ± 0.05 1.27 ± 0.14 NS
Duration (weeks) 48 ± 25* 120 ± 41* 64 ± 26 p < 0.05
FEV1 (% predicted) 102.0 ± 2.7* 78.8 ± 5.0* 84.2 ± 7.7* p < 0.001 (1 v. 2)
p < 0.05 (1 v. 3)
FVC (% predicted) 105.4 ± 3.2* 87.1 ± 4.5* 87.6 ± 7.6* p < 0.01 (1 v. 2)
p < 0.05 (1 v. 3)
FEV1/FVC (%) 85.3 ± 1.6 78.2 ± 2.9 82.1 ± 3.5 NS
DLCOc (% predicted) 97.6 ± 3.9* 82.2 ± 3.0* 68.8 ± 6.1* p < 0.001 (1 v.3)
p < 0.05 (1 v. 2)
BALF lymphocytes (%) 57 ± 6 37 ± 6 42.4 ± 9.6 NS
SACE 57.0 ± 6.0 53.6 ± 10.8 92.7 ± 31.8 NS
CRP 20.6 ± 8.0 8.5 ± 1.4 3.7 ± 1.2 NS
Ca2+ serum [mmol/ml] 2.42 ± 0.03 2.44 ± 0.03 2.50 ± 0.03 NS
Ca2+ 24 hrs urine [mmol/24 hrs] 5.46 ± 0.61 6.70 ± 1.10 6.76 ± 1.11 NS
#BALF HGF was measured in 30 patients; *Significantly different
BALF — bronchoalveolar lavage fluid, CRP — C-reactive protein, DLCOc — diffusing capacity for CO corrected for haemoglobin concentration, EBC — exhaled breath con-
densate, FEV1 — forced expiratory volume in 1st second, FVC — forced vital capacity, HGF — hepatocyte growth factor, NS — not significant, LS — Löfgren syndrome,
SACE — serum angiotensin converting enzyme
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Neither the EBC nor BALF concentrations in
sarcoidosis patients correlated with radiological
stage, the presence or absence of Löfgren syndro-
me, number of relapses and duration of disease,
lung function parameters, BALF lymphocyte per-
centage/number, SACE, serum CRP, serum calcium
concentrations, and 24-hour urinary calcium loss.
Table 1 shows the results and characteristics
of the study group.
Discussion
One of most intriguing questions in sarco-
idosis research is how to distinguish patients po-
sing a risk of developing lung fibrosis, who co-
uld possibly benefit from long-term treatment,
from those with good prognosis, in whom the
disease will vanish eventually without any con-
sequences. HGF is thought to be a promising
molecule in this context, as its production was
increased in several clinical situations charac-
terized by lung epithelial damage with subsequent
regeneration [6, 8, 9].
Despite its mitogenic activity towards epithe-
lial cells, several additional mechanisms of antifi-
brotic action of HGF have been proposed:
— down-regulation of fibrogenic cytokines, such
as transforming growth factor b (TGF-b), pla-
telet-derived growth factor (PDGF), and con-
nective tissue growth factor (CTGF) [11];
— inhibition of myofibroblast differentiation and
overgrowth [12];
— induction of myofibroblast apoptosis [13];
An additional potential role of HGF in the
pathogenesis of sarcoidosis may be a consequence
of the suppression of antigens presenting activi-
ty of dendritic cells [14]. This may result in in-
hibition of further pathogenetic steps, leading
through recognition of antigen-MHC complex
linked to T-cell receptor and differentiation of
Th0 to Th1 cells to oligoclonal proliferation of
lymphocytes.
The following scenarios were taken into acco-
unt: 1. providing HGF reflects the extent of epithe-
lial damage, higher concentrations should have
been expected in patients with extensive parenchy-
mal involvement and worse LFT results; 2. assu-
ming HGF is a molecule necessary for effective
epithelial healing, the lack of its increase in respon-
se to damage may switch the regenerative pathway
into extensive fibrosis. In this case, lower HGF in
EBC or BALF could contribute to identifying pa-
tients with a worse prognosis. To strengthen the
possibility of the latter, Marchand-Adam et al. [15,
16] suggested a severely defective secretion and
activation of HGF by lung fibroblasts in idiopathic
pulmonary fibrosis (IPF).
Our results, however, do not confirm any of
these hypotheses. This might be accounted for by
the following:
1. Even in very profound interstitial involvement
in sarcoidosis, extensive epithelial damage
rarely occurs. This is possible, considering the
histopathology of sarcoid lung, overall good
prognosis, and clinical observations showing
a sporadic reversibility of sometimes very
extensive interstitial changes.
2. The character of defects in HGF production
may vary. The temporal lack of HGF increase
(or decrease) in response to certain devasta-
ting stimuli may be difficult to capture in
a clinical setting.
Regardless, of which of the above statements
is true, HGF in BALF and EBC should not be re-
commended as a prognostic marker in sarcoidosis.
Conclusions
1. HGF is detectable in EBC and BALF, both in
sarcoidosis patients and in healthy subjects.
2. HGF concentrations do not distinguish sar-
coidosis patients from healthy subjects and
do not correlate with chosen activity and pro-
gnostic markers. Thus, the HGF concentra-
tion level is unavailing as a biomarker in sar-
coidosis.
3. Further studies are needed (comprising more
patients with progressive disease, follow-up
studies, etc) in order to definitely disqualify
this biomarker for sarcoidosis monitoring.
Figure 1. HGF concentration in bronchoalveolar lavage fluid (BALF)
and exhaled breath condensate (EBC) in healthy controls (C) and
patients with sarcoidosis (S)
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